VisionHealth
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler. Whether asthma therapy or COPD therapy - our digital solution Kata® enhances inhalation therapy and trains patients with many respiratory diseases to use their inhalers effectively. The inhalation device supports them in avoiding shortness of breath and hospital stays.
VisionHealth
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler. Whether asthma therapy or COPD therapy - our digital solution Kata® enhances inhalation therapy and trains patients with many respiratory diseases to use their inhalers effectively. The inhalation device supports them in avoiding shortness of breath and hospital stays.
TL;DR
Product: Kata® — AI-based smartphone inhalation coach and analytics platform (CE-marked / medical device)
Headquarters: Munich, Germany (with a U.S. subsidiary and Boston-area presence)
Founding year: 2017
Recent funding: €3.0M pre-Series A announced Feb 27, 2023
Employees: Approximately 20
Company Overview
Problem Domain
Adherence and technique optimization for inhaled therapies in respiratory diseases (asthma, COPD).
Founded
2017
Industry
Digital health / Digital therapeutics / Medical devices
Funding Track Record
€3.0M
Announced to finance extended COPD and asthma study and regulatory/commercial preparation
€1.5M
Round included existing shareholders and new investors such as Dr. Thomas Ecker and Vantage Value GmbH
Investor Signal
“Investors include DB Specialty Invest, Sanner Ventures, Dr. Thomas Ecker and Vantage Value GmbH”